SCHEMBL1744293

SCHEMBL1744293

COc1ccc(-c2cc(=O)c3ccc(O)cc3o2)cc1O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 3/20 0.71
TNKS2 Q9H2K2 3/20 0.71
PARP1 P09874 2/20 0.71
ALOX5 P09917 1/20 0.71
POLH Q9Y253 1/20 0.71
PABPC1 P11940 1/20 0.71
CYP3A4 P08684 5/20 0.70
MEN1 O00255 4/20 0.70
CYP2C9 P11712 4/20 0.70
KMT2A Q03164 4/20 0.70
CYP2C19 P33261 3/20 0.70
TP53 P04637 2/20 0.70
CYP1A1 P04798 3/20 0.70
CYP1B1 Q16678 3/20 0.70
IP6K2 Q9UHH9 2/20 0.70
KDM1A O60341 1/20 0.70
CYP1A2 P05177 1/20 0.70
ABCC1 P33527 1/20 0.70
XDH P47989 1/20 0.70
IPMK Q8NFU5 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30960382 1.00 TNKS (0.71) TNKSTNKS2PARP1ALOX5POLH
SCHEMBL4400168 0.91 FYN (0.81) TNKSTNKS2PARP1ALOX5POLH
SCHEMBL9663466 0.90 CSNK2A2 (0.81) TNKSTNKS2PARP1ALOX5POLH
SCHEMBL29435863 0.90 CSNK2A2 (0.81) TNKSTNKS2CYP3A4MEN1CYP2C9
SCHEMBL29435862 0.90 CSNK2A2 (0.81) TNKSTNKS2PARP1ALOX5POLH
SCHEMBL29929667 0.90 CSNK2A2 (0.81) TNKSTNKS2PARP1ALOX5POLH
SCHEMBL26117897 0.90 CSNK2A2 (0.81) TNKSTNKS2CYP3A4MEN1CYP2C9
SCHEMBL8934505 0.87 CYP1A1 (0.69) CYP3A4MEN1CYP2C9KMT2ACYP2C19
SCHEMBL5320080 0.86 KDM4E (0.81) TNKSTNKS2PARP1ALOX5POLH
SCHEMBL8934484 0.84 CSNK2A2 (0.60) TNKSTNKS2PARP1ALOX5POLH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9386787-B2 Preparations for oral consumption SYMRISE AG (DE) 2016-07-12 US disclosed
US-20140134114-A1 PREPARATIONS FOR ORAL CONSUMPTION SYMRISE AG (DE) 2014-05-15 US disclosed
EP-2386211-A1 Use of rubusoside to reduce or suppress particular unpleasant taste sensations Symrise AG (DE) 2011-11-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140134114-A1 PREPARATIONS FOR ORAL CONSUMPTION TAS1R1, TAS2R16, TAS2R1 TNKS 4790/4885TNKS2 4867/4885PARP1 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.